David Garcia Cervetti

Array ( [id] => 17929815 [patent_doc_number] => 20220324940 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-13 [patent_title] => CONSTRUCTION OF CHIMERIC ANTIGEN RECEPTOR TARGETING CD20 ANTIGEN AND ACTIVITY IDENTIFICATION OF ENGINEERED T CELLS THEREOF [patent_app_type] => utility [patent_app_number] => 17/723859 [patent_app_country] => US [patent_app_date] => 2022-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9839 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17723859 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17830423 [patent_doc_number] => 20220267727 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => GENE-REGULATING COMPOSITIONS AND METHODS FOR IMPROVED IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 17/707789 [patent_app_country] => US [patent_app_date] => 2022-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 82512 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17707789 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19521309 [patent_doc_number] => 12123021 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-22 [patent_title] => Gene-regulating compositions and methods for improved immunotherapy [patent_app_type] => utility [patent_app_number] => 17/707725 [patent_app_country] => US [patent_app_date] => 2022-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 33 [patent_no_of_words] => 82511 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17707725 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19584830 [patent_doc_number] => 20240382387 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-21 [patent_title] => DENTAL COMPOSITION AND DENTINE CULTURING METHOD [patent_app_type] => utility [patent_app_number] => 18/564869 [patent_app_country] => US [patent_app_date] => 2022-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6376 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18564869 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19439987 [patent_doc_number] => 12090213 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-17 [patent_title] => Smart exosomes for active PDAC targeting and evading mononuclear phagocytotic system [patent_app_type] => utility [patent_app_number] => 18/550503 [patent_app_country] => US [patent_app_date] => 2022-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 43 [patent_no_of_words] => 7686 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18550503 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20127970 [patent_doc_number] => 12370270 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-29 [patent_title] => Methods for distributing high levels of therapeutic agent throughout the cortex to treat neurological disorders [patent_app_type] => utility [patent_app_number] => 17/697841 [patent_app_country] => US [patent_app_date] => 2022-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 14597 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17697841 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17881158 [patent_doc_number] => 20220296635 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-22 [patent_title] => Compositions Comprising Citrate and Applications Thereof [patent_app_type] => utility [patent_app_number] => 17/691518 [patent_app_country] => US [patent_app_date] => 2022-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11858 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17691518 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19793515 [patent_doc_number] => 12234449 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-25 [patent_title] => CRISPR/Cas-related methods and compositions for treating Leber's congenital amaurosis 10 (LCA10) [patent_app_type] => utility [patent_app_number] => 17/688782 [patent_app_country] => US [patent_app_date] => 2022-03-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 75 [patent_figures_cnt] => 80 [patent_no_of_words] => 96949 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17688782 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17640713 [patent_doc_number] => 20220168451 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-02 [patent_title] => SYNTHETIC DNA VECTORS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/675899 [patent_app_country] => US [patent_app_date] => 2022-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45534 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17675899 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19083352 [patent_doc_number] => 20240110153 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-04 [patent_title] => Surface Modified Red Blood Cells And Methods Of Generating The Same [patent_app_type] => utility [patent_app_number] => 18/274649 [patent_app_country] => US [patent_app_date] => 2022-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21169 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18274649 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17761760 [patent_doc_number] => 20220235372 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-28 [patent_title] => USE OF NOVEL MIRNA-BINDING SITE CASSETTES FOR ANTIGEN-PRESENTING CELL DETARGETING OF TRANSGENE EXPRESSION BY RAAV GENE THERAPY VECTORS [patent_app_type] => utility [patent_app_number] => 17/581306 [patent_app_country] => US [patent_app_date] => 2022-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25441 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17581306 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20077809 [patent_doc_number] => 12351862 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-08 [patent_title] => Crisscross cooperative self-assembly [patent_app_type] => utility [patent_app_number] => 17/576550 [patent_app_country] => US [patent_app_date] => 2022-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 64 [patent_no_of_words] => 14659 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17576550 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17561800 [patent_doc_number] => 20220125949 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-28 [patent_title] => GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE II [patent_app_type] => utility [patent_app_number] => 17/573883 [patent_app_country] => US [patent_app_date] => 2022-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47047 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 113 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17573883 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17561803 [patent_doc_number] => 20220125952 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-28 [patent_title] => DELIVERY OF POLYNUCLEOTIDES USING RECOMBINANT AAV9 [patent_app_type] => utility [patent_app_number] => 17/573303 [patent_app_country] => US [patent_app_date] => 2022-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16714 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17573303 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17563077 [patent_doc_number] => 20220127226 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-28 [patent_title] => ANTI-ARRHYTHMICITY AGENTS [patent_app_type] => utility [patent_app_number] => 17/573442 [patent_app_country] => US [patent_app_date] => 2022-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17364 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17573442 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18517657 [patent_doc_number] => 11707528 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-07-25 [patent_title] => Mannose-based mRNA targeted delivery system and use thereof [patent_app_type] => utility [patent_app_number] => 17/559620 [patent_app_country] => US [patent_app_date] => 2021-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 14 [patent_no_of_words] => 5862 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17559620 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18574319 [patent_doc_number] => 11730825 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-22 [patent_title] => Lipid nanoparticle compositions and methods for mRNA delivery [patent_app_type] => utility [patent_app_number] => 17/558310 [patent_app_country] => US [patent_app_date] => 2021-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 17976 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17558310 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17807733 [patent_doc_number] => 20220259568 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-18 [patent_title] => COMPOSITIONS AND METHODS FOR ENHANCED GENE EXPRESSION IN CONE CELLS [patent_app_type] => utility [patent_app_number] => 17/556847 [patent_app_country] => US [patent_app_date] => 2021-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29178 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17556847 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17532462 [patent_doc_number] => 20220111071 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-14 [patent_title] => LIPID NANOPARTICLE COMPOSITIONS AND METHODS FOR MRNA DELIVERY [patent_app_type] => utility [patent_app_number] => 17/556978 [patent_app_country] => US [patent_app_date] => 2021-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17921 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17556978 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18116392 [patent_doc_number] => 11547764 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-10 [patent_title] => Lipid nanoparticle compositions and methods for MRNA delivery [patent_app_type] => utility [patent_app_number] => 17/556573 [patent_app_country] => US [patent_app_date] => 2021-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 17978 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 129 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17556573 [rel_patent_id] =>[rel_patent_doc_number] =>)